Home>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Glucose Transporters>>SLC26A3-IN-2

SLC26A3-IN-2

Catalog No.GC71079

SLC26A3-IN-2 is an orally active inhibitor of anion exchanger protein SLC26A3 (IC50=360 nM).

Products are for research use only. Not for human use. We do not sell to patients.

SLC26A3-IN-2 Chemical Structure

Cas No.: 950348-60-4

Size Price Stock Qty
5 mg
$81.00
In stock
10 mg
$135.00
In stock
25 mg
$279.00
In stock
50 mg
$450.00
In stock
100 mg
$720.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
SLC26A3-IN-2 is an orally active inhibitor of anion exchanger protein SLC26A3 (IC50=360 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea.

SLC26A3-IN-2 (compound 3a) (10 μM; 10 min) produces 92% inhibition rate against SLC26A3[1].

SLC26A3-IN-2 (10 mg/kg; po) significantly increases stool weight and number of pellets in a Loperamide -induced model of constipation in mice, demonstrating its efficacy in increasing stool hydration in mice[1].

References:
[1]. Cil O, et al. Small molecule inhibitors of intestinal epithelial anion exchanger SLC26A3 (DRA) with a luminal, extracellular site of action. Eur J Med Chem. 2023 Mar 5;249:115149.

Reviews

Review for SLC26A3-IN-2

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SLC26A3-IN-2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.